#OpenAccess journal covering the translational pipeline for #immunotherapy 🎯Included in WoS, PubMed & Scopus Official @britsocimm journal | EiC: Prof @tim_tje
Joined June 2020
- Tweets1.4K
- Following337
- Followers1.2K
- Likes636
Pinned Tweet
Immunotherapy Advances publishes from discovery through to clinical trials - now more accessible than ever thanks to read & publish.
Make your science count beyond the lab bench.
Read more about read and publish here: bit.ly/4ksUbHJ
Immunotherapy Advances Journal retweeted
It’s Open Access Week! Publishing open access makes immunology research accessible to all #OAWeek 🔓
BSI members can save 20% on publication fees in DSI and ITA, or 33% on open access fees in CEI.
Find out more about support for open access publishing: vist.ly/5pnmm
New research in ITA suggests age related differences in how children and adults process immunoglobulin replacement therapy are unlikely to be clinically meaningful.
The findings support dosing guided by individual needs, rather than age alone.
Read more: academic.oup.com/immunothera…
A simple whole-blood assay enables rapid, in vivo monitoring of engineered TCR T cell function, capturing cytokine responses post-transfer without complex processing. A practical step for tracking cell therapy performance. 🧬
vist.ly/5mnx8
A step forward in evolving cell therapies for AML: integrating TCR, CAR, BiTE, and safety switch into a single engineered T cell highlights how the field is moving toward multi-functional, adaptable designs to overcome tumor complexity.
vist.ly/5mcnu
📢 New open‑access study shows MAGE‑A4‑specific TCR‑NK cells combine innate NK killing with targeted TCR activity ,offering a potent, safe, “off‑the‑shelf” strategy for solid tumors.
🔗 vist.ly/5k2iy
📢 Pediatric PID study: fSCIG 10% maintains stable IgG levels in children aged 2–<16 years, with consistent pharmacokinetics across age groups and support for every‑3–4‑week dosing, helping reduce treatment burden without compromising efficacy.
🔗 vist.ly/5kqy3
A high-affinity ImmTAC® bispecific efficiently redirects T cells to target PRAME+ tumour cells, even at very low antigen levels, highlighting its promise across multiple cancers 🧬
🔗 vist.ly/5mz8r
#Immunotherapy #CancerResearch #Tcells #OpenAccess
🧬 Open‑access study shows how spatial immune architecture and macrophage polarization shape immunotherapy responses in mismatch repair–deficient colorectal cancer, helping explain why metastatic lesions respond differently.
👉 vist.ly/5kesq
#Immunotherapy
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders.
Read here📄 bit.ly/4pw1rVL
How Streptococcus pneumoniae interacts with innate immunity matters. New open‑access research shows neuraminidase A (NanA) shapes immune sensing and phagocytic clearance in microglia and macrophages, with implications for pneumococcal meningitis.
doi.org/10.1093/immadv/ltag0…
Open‑access review explores how targeting monocyte dynamics could offer new therapeutic approaches for multiple sclerosis, with insights from experimental models highlighting monocyte plasticity and inflammation resolution.
vist.ly/5jhn9
This study maps the spatial + immune landscape of metastatic dMMR colorectal cancer, revealing why some lesions respond to immunotherapy while others resist. Macrophage polarization and spatial immune architecture emerge as key drivers of outcome.
🔗 vist.ly/5ixaq
Immunotherapy Advances Journal retweeted
It's #PeerReviewWeek and we want to extend our thanks and recognition to the valuable contributions of peer reviewers.
Thank you to all who generously give their time and expertise to improve the quality of research published in our journals and beyond!
This review explores the bottom-up development of LGR5-targeting immunotherapeutics, showing how a highly specific α‑LGR5 antibody can be adapted into multiple modalities
📖 Read more: vist.ly/5ihju
Submissions are still open for our CD40 turns 40 Special Collection, exploring four decades of CD40 biology and its impact on immunotherapy across cancer, autoimmunity, and more 🧬
Learn more about submitting here: academic.oup.com/immunothera…
#Immunology #Immunotherapy
Immunotherapy Advances Journal retweeted
We're at #BSICambridge26 today! if you're attending, do come and say hello and ask us about our membership, journals and professional development opportunities.
Check out this open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access.
vist.ly/5gcug
🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it.
Read: doi.org/10.1093/immadv/ltaf0…
🔬 Can we better monitor responses to JAK inhibitors?
This study presents two flow cytometry assays with potential as biomarkers for treatment monitoring and personalized care.
📄 doi.org/10.1093/immadv/ltaf0…
🧬 Higher levels of regulatory B cells were linked to poorer outcomes and weaker responses to immunotherapy in clear cell renal cell carcinoma, highlighting a potential new target for treatment.
🔗 doi.org/10.1093/immadv/ltaf0…
